Collectively, the profound progress during the past decades in the molecular and cellular mechanisms and cancer biology of FAK has provided much basic and clinical medical knowledge for targeting FAK as a potential anticancer therapeutic strategy. This evidence concerns the gene PTK2 and cancer.